RS1-related retinoschisis gene therapy for vision improvement
Part of Eyes & vision clinical trials.
This Phase 3 trial tests a gene therapy (ATSN-201) to improve or preserve vision in people with RS1-associated X-linked retinoschisis (XLRS), a genetic eye condition. You may qualify if you have a certain level of vision and specific eye “schisis” changes seen on a scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (or age 6 to under 18 in a specific study group).
- Your XLRS must be caused by an RS1 gene mutation, confirmed by a genetic diagnosis (and the study also allows certain female genetic patterns).
- In the study eye, your vision must be between 20/200 and 20/40 (about 34 to 73 ETDRS letters).
- Your eye scan must show a foveal schisis (and the study may also consider parafoveal/perifoveal schisis).
- No major eye problems that would raise the risk of vision loss from a retinal injection (like advanced glaucoma, optic nerve damage, severe eye inflammation, or corneal transplant).
- No eye surgery (including laser) in the past 6 months, and none planned for the first year of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single gene therapy injection under the retina for boys with X-linked retinoschisis, a condition that causes vision loss. It aims to see if the treatment is safe and can improve vision.
This trial studies whether LX103 can improve vision and is safe for people with X-linked retinoschisis (XLRS) caused by RS1 gene changes. It focuses on a specific level of vision in the study eye and checks for medical conditions that could affect eye testing or safety.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests an experimental gene therapy (OPGx-RDH12-1001) injected under the retina to treat a rare form of inherited vision loss called LCA caused by RDH12 gene mutations. It aims to see if the treatment is safe and tolerable for people with advanced vision loss.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
This Phase 1/2 study tests a gene therapy treatment (BS01) in people with retinitis pigmentosa to try to improve or preserve vision. You may be a candidate if your vision in at least one eye is quite limited and you haven’t had certain gene therapies before.
Hear when a new X-linked Retinoschisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.